AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $80.10.

A number of brokerages have issued reports on ANAB. Wedbush upped their target price on AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th. HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of AnaptysBio in a research note on Monday. Stifel Nicolaus upped their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Wall Street Zen downgraded shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Barclays raised their price objective on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th.

Insiders Place Their Bets

In other AnaptysBio news, CEO Daniel Faga sold 17,679 shares of the stock in a transaction that occurred on Friday, March 27th. The stock was sold at an average price of $61.61, for a total transaction of $1,089,203.19. Following the transaction, the chief executive officer owned 495,965 shares of the company’s stock, valued at $30,556,403.65. This trade represents a 3.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul F. Lizzul sold 4,219 shares of AnaptysBio stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $43.26, for a total value of $182,513.94. Following the completion of the transaction, the insider owned 33,303 shares of the company’s stock, valued at approximately $1,440,687.78. The trade was a 11.24% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 110,193 shares of company stock valued at $5,333,138. 33.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently made changes to their positions in the company. Smartleaf Asset Management LLC boosted its holdings in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its position in shares of AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the last quarter.

AnaptysBio Price Performance

Shares of ANAB stock opened at $55.46 on Wednesday. The company’s fifty day moving average price is $55.67 and its two-hundred day moving average price is $44.24. The firm has a market capitalization of $1.59 billion, a P/E ratio of -106.65 and a beta of 0.32. AnaptysBio has a 12 month low of $15.40 and a 12 month high of $68.39.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. The business had revenue of $108.25 million for the quarter, compared to analyst estimates of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, sell-side analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in outstanding shares. This buyback authorization authorizes the biotechnology company to reacquire up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.